• Ton Lisman, Pieter W Kamphuisen, Patrick G Northup, and Robert J Porte.
• Department of Surgery, Section of Hepatobiliairy Surgery and Liver Transplantation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. j.a.lisman@umcg.nl
• J. Hepatol. 2013 Aug 1; 59 (2): 358-66.

AbstractUntil recently, it was widely accepted that patients with cirrhosis have a bleeding tendency related to the changes in the hemostatic system that occur as a consequence of the disease. However, it has now been well established that patients with cirrhosis are at risk for both bleeding and thrombotic complications. These thrombotic complications include portal vein thrombosis, deep vein thrombosis and pulmonary embolism, and coronary or cerebrovascular infarctions. Antithrombotic drugs to prevent or treat thrombotic complications in patients with cirrhosis have been used only minimally in the past due to the perceived bleeding risk. As the thrombotic complications and the necessity of antithrombotic treatment in these patients are increasingly recognized, the use of antithrombotic drugs in this population is likely increasing. Moreover, given the rising incidence of fatty liver disease and generally longer survival times of patients with chronic liver diseases, it would be reasonable to presume that some of these thrombotic complications may be increasing in incidence over time. In this review, we will outline the indications for antithrombotic treatment in patients with cirrhosis. Furthermore, we will discuss the available antithrombotic drugs and indicate possible applications, advantages, and caveats. Since for many of these drugs very little experience in patients with cirrhosis exists, these data are essential in the design of future clinical and laboratory studies on mechanisms, efficacy, and safety of the various antithrombotic strategies in these patients. Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

68 keywords...

hide…